Fig. 1: Talazoparib synergises with carboplatin in most TNBC cell lines. | British Journal of Cancer

Fig. 1: Talazoparib synergises with carboplatin in most TNBC cell lines.

From: Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer

Fig. 1

IC50 values for (a) talazoparib, and (b) carboplatin in TNBC cell lines. Data are mean + /− SEM. The dashed line indicates the median IC50 value for all cell lines for that therapeutic agent. Effect of the combination of talazoparib and carboplatin demonstrated in (c) by combination index values reported at an FA of 0.5. Under each cell line is the dose-reduction index (DRI) for talazoparib and carboplatin. Teal green bars/dots represent BRCAWT cell lines, and pink bars/dots represent BRCAMUT cell lines.

Back to article page